Anti-tumor effects of an ID antagonist with no observed acquired resistancePaulina M. Wojnarowicz, Robert Benezra|npj Breast Cancer|2021Cited by 28
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G. Thomson, Savithri Ramurthy, Alan C. Rigby et al.|Journal of Medicinal Chemistry|2024Cited by 16
1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cellsJeremy Drees, Nandita Bose, Anissa Chan et al.|Regular and Young Investigator Award Abstracts|2022Cited by 5
Anti-tumor effects of an Id antagonist with no acquired resistancePaulina M. Wojnarowicz, Robert Benezra|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 3
Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer modelsFeven Tameire, Nandita Bose, Paulina M. Wojnarowicz et al.|Cancer Research|2023Cited by 3